IRulya Therapeutics Inc. - 8-K Filing

IRulya Therapeutics Inc. posted an updated Corporate Presentation on its website outlining pipeline progress for inhaled rapamycin (LAM-001) and provided details of anticipated clinical milestones. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $QNCX

Read the full article at SEC EDGAR

Part of the story Silence Therapeutics plc - 8-K Filing (3 articles)

More Regulatory news